大麻素信号在急性和慢性肾脏疾病中的作用
本文综述了内源性大麻素系统(ECS)在肾脏疾病中的临床前证据,指出ECS参与糖尿病肾病、药物肾毒性和进展性慢性肾脏病的发病机制,且药理调控ECS在实验动物中具有肾脏保护作用。同时,合成大麻素使用与急性肾损伤(AKI)相关,应纳入AKI鉴别诊断,尤其在年轻人群中。
要点
- 内源性大麻素系统在肾脏中完整存在,参与糖尿病肾病、药物肾毒性和慢性肾脏病进展。
- 药理调控ECS在实验动物中显示肾脏保护效应,有望未来应用于人类。
- 合成大麻素相关AKI应纳入鉴别诊断,尤其在年轻患者中。
核心结论
- 内源性大麻素系统在肾脏疾病发病中具有重要作用,药理调控可能成为未来治疗靶点。
- 合成大麻素使用与急性肾损伤相关,应引起临床关注。
研究设计与样本
- 综述,总结临床前证据及合成大麻素相关AKI的病例报告。
主要发现
- 内源性大麻素anandamide和2-arachidonoylglycerol结合1型和2型大麻素受体。
- 肾脏存在完整的内源性大麻素系统,参与糖尿病肾病、药物肾毒性和进展性慢性肾脏病。
- 药理调控内源性大麻素系统在实验动物中具有肾脏保护作用。
- 合成大麻素相关AKI病例报告显示其效力和毒性率高于天然大麻。
临床怎么用
- 在AKI鉴别诊断中,尤其年轻患者,应考虑合成大麻素使用可能。
- 内源性大麻素系统调控作为肾脏保护策略尚需进一步临床验证。
局限性
- 综述基于临床前证据和病例报告,缺乏人体干预研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The endogenous cannabinoids anandamide and 2-arachidonoylglycerol bind to the cannabinoid receptors of type 1 and 2. These receptors are also the binding sites for exogenous, both natural and synthetic, cannabinoids that are used for recreation purposes. Until recently, cannabinoids and cannabinoid receptors have attracted little interest among nephrologists; however, a full endocannabinoid system (ECS) is present in the kidney and it has recently emerged as an important player in the pathogenesis of diabetic nephropathy, drug nephrotoxicity, and progressive chronic kidney disease. This newly established role of the ECS in the kidney might have therapeutic relevance, as pharmacological modulation of the ECS has renoprotective effects in experimental animals, raising hope for future potential applications in humans. In addition, over the last years, there has been a number of reported cases of acute kidney injury (AKI) associated with the use of synthetic cannabinoids that appear to have higher potency and rate of toxicity than natural Cannabis. This poorly recognized cause of renal injury should be considered in the differential diagnosis of AKI, particularly in young people. In this review we provide an overview of preclinical evidence indicating a role of the ECS in renal disease and discuss potential future therapeutic applications. Moreover, we give a critical update of synthetic cannabinoid-induced AKI.
引用
- Barutta F, Bruno G, Mastrocola R, et al. The role of cannabinoid signaling in acute and chronic kidney diseases. Kidney Int. 2018. PMID: 29706358. doi:10.1016/j.kint.2018.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。